Press Releases
Selcia and Gilead Sciences Extend Liver Disease Drug Discovery Collaboration
Selcia Limited, a leading contract research organisation, announced a drug discovery collaboration agreement with Gilead Sciences, Inc. Building on an established partnership following significant progress made to date, Selcia’s chemists and biologists will continue to provide integrated drug discovery...
Press Releases
BG Medicine Announces FDA Clearance of its Galectin-3 Test for Use in Patients with Chronic HF
BG Medicine, Inc., a U.S.-based life sciences company, announced that the U.S. FDA has cleared the company’s Galectin-3 test for use in conjunction with clinical evaluation as an aid to assess the prognosis of patients diagnosed with chronic heart...
Press Releases
NanoString Launches First Simple and Precise Approach to Detect Hundreds of Genetic Copy Variants in a Single Multiplexed Reaction
NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, announced the launch of a novel solution for detecting genetic copy number variations (CNVs)...
Press Releases
Merrion Pharmaceuticals Plc announces commencement of feasibility and option agreement with Rebel Pharmaceuticals
Merrion Pharmaceuticals Plc, a publicly listed product development company, announced the commencement of an oral drug delivery feasibility and option agreement with Rebel Pharmaceuticals, LLC, on two undisclosed compounds. The agreement will evaluate the ability of Merrion's patented GIPET®...
Press Releases
Abbott Announces Positive Results from Phase 2 Study of Low Dose Atrasentan for Treatment of Diabetic Kidney Disease
Abbott announced positive results from a Phase 2 dose-ranging study of atrasentan, a highly selective endothelin A receptor (ETAR) antagonist in development to help slow chronic kidney disease (CKD) progression in patients with type 2 diabetic nephropathy (diabetic kidney...
Press Releases
Reata and Abbott Announce Positive Phase 2b Study Results for Bardoxolone Methyl
Reata Pharmaceuticals and Abbott announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce the stage of CKD and improve estimated glomerular filtration rate (eGFR) and other...
Press Releases
Novartis unveils long-term strategy to grow in a dynamically changing healthcare environment
Novartis presented today a strategic overview of the company's diversified healthcare portfolio which creates the potential for future sustainable growth. The company's focused healthcare portfolio across key growth segments in healthcare provides Novartis a leading position in the respective...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read